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ABSTRACT 
 
INVESTIGATION OF STILBENE-FUSED CHALCONE AND 
FLAVANONE DERIVATIVES FOR THEIR CYTOTOXIC AND ANTI-
CANCER PROPERTIES 
 
Stilbene, chalcone and flavanones are three major classes of molecules, which 
can be found in plants as secondary metabolites. Derivatives of those may possess 
variety of biological activities. In this study it is aimed to synthesize a hybrid molecule 
which may show the biological activities of both flavanone and stilbene, or chalcone 
and stilbene simultaneously. For this purpose previously synthesized 11 simple 
chalcone, flavanone and stilbene derivatives and 31 stilbene-fused chalcones and 
stilbene-fused flavanones were tested for their cytotoxic activities in prostate cancer cell 
line (PC-3) and breast cancer cell line (MCF-7) by using MTT assay. Then aromatase 
inhibition properties of simple chalcones, flavanones, stilbenes, stilbene-fused 
chalcones and stilbene-fused flavanones were studied.  
Results of the study were evaluated in potential of the hybrid system to carry out 
more than one biological activity and mimicking performance of the simple ones. 
Results indicate that tested simple chalcone and flavanone derivatives are more 
cytotoxic than simple stilbenes in both cancer cell lines. On the contrary, simple stilbene 
structures were much more successful in aromatase inhibition assays. Cytotoxic activity 
profiles of stilbene-fused chalcones in cancer cells show that those molecules mostly 
mimic the simple chalcone structures. On the other hand, flavanones lost their cytotoxic 
activities when they were fused with stilbenes. In addition, aromatase inhibition assay 
showed that stilbene-fused chalcones again do mimic the simple chalcones but not 
simple stilbenes. In the same assays, stilbene-fused flavanones may mimic both simple 
flavanones and simple stilbenes by depending on the type and position of the substituent 
in terminal aromatic rings.  
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ÖZET 
 
SİTİLBEN KAYNAŞTIRILMIŞ ÇALKON VE FLAVANON 
TÜREVLERİNİN SİTOTOKSİK VE ANTİ-KANSER 
ÖZELLİKLERİNİN İNCELENMESİ 
 
Bitkilerde bulunan sekonder metabolitlerin üç temel sınıfını oluşturan sitilben, 
çalkon ve flavanonlar ve onların türevleri çeşitli biyolojik aktivitelere sahiptir. Bu 
çalışmada, flavanon-sitilben yapılarının veya çalkon-sitilben yapılarının biyolojik 
aktivitelerine aynı anda sahip hibrid moleküller sentezlemek amaçlanmıştır. Bunun için 
sentezleri daha önce gerçekleştirilen 11 basit çalkon, flavanon ve sitilben türevleri ile 31 
sitilben-kaynaştırılmış çalkon ve sitilben-kaynaştırılmış flavanonların sitotoksik 
özellikleri prostat kanseri hücre hattı (PC-3) ve meme kanseri hücre hattında (MCF-7) 
MTT ile test edildi. Daha sonra bu maddelerin aromataz enzimi üzerindeki baskılayıcı 
etkileri araştırıldı. 
Sonuçlar iki ana başlık altında değerlendirildi; birincisi hibrid moleküllerin 
birden fazla biyolojik aktiviteyi taşıma potansiyeli, ikincisi ise hibrid moleküllerin basit 
yapıların özelliklerini taklit etme yetenekleri. Sonuçlar gösteriyor ki, basit çalkon ve 
flavanon türevleri her iki kanser hücresi hattında da basit sitilbenlere göre daha yüksek 
sitotoksik etkiye sahiptirler. Bunun aksine basit sitilbenler aromataz enzimini inhibe 
etmede basit çalkon ve flavanonlardan daha başarılıdır. Sitilben-kaynaştırılmış 
çalkonların sitotoksik özellikleri de bu maddelerin çoğunlukla basit çalkonları taklit 
ettiğini göstermektedir. Diğer taraftan, flavanonlar sitilbenlerle kaynaştırıldığında 
sitotoksik aktivitelerini kaybetmektedir. Ayrıca aromataz inhibisyon çalışmalarında, 
sitilben-kaynaştırılmış çalkonların basit sitilbenleri değil basit çalkon yapılarını taklit 
ettiği görülmüştür. Sitilben-kaynaştırılmış flavanonlar ise terminal aromatik 
halkalarındaki substituentlerin türüne ve pozisyonuna bağlı olarak hem basit 
flavanonları hem de basit sitilbenleri taklit edebilmektedir. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1. The Cell, Apoptosis and Cancer 
 
The cell is the smallest functional unit of any living organisms which can be 
classified as unicellular or multicellular. Humans contain about 10 trillion (10
13
) cells 
and the body makes up many types of cells. When the body is healthy cells grow and 
divide in a controlled way to produce more cells. In a normal process when cells 
become old or damaged, they die or are replaced with new cells. Cell death can be 
described as either apoptosis or necrosis. Apoptosis which is a normal physiological 
process of cell suicide is encoded in the chromosomes of all nucleated cells. 
Physiological cell death, which is a firmly controlled and finely organized event, plays a 
significant role in development, tissue homeostasis, and defense against viral infection 
and mutation by removing unnecessary and damaged cells. Apoptosis is regulated by a 
several range of cell signals, which may arise either extracellularly or intracellularly and 
may affect apoptosis positively or negatively. In an apoptotic process, the cell shrinks 
and separate from neighboring cells, thereby it dies with minimal harm to nearby cells 
compare to necrosis which is characterized by inflammation and widespread damage.[1]  
The mutations, which occur through errors in the replication of deoxyribonucleic 
acid (DNA) during cell division or after exposure to a carcinogen, cause the loss of a 
cell’s ability to undergo apoptosis and affect the normal cell growth and division. When 
this happens, cells continue to grow and form new and abnormal cells instead of dying. 
Thus, the balance between the rates of new cell growth and old cell death is 
disrupted.[2] This abnormality in cell growth and multiplication is called cancer, which 
is a general name for a more than 200 diseases in which cells in a part of the body begin 
to grow out of control, and occurs because of environmental factors (such as cigarette 
smoking or radiation exposure), viral factors, a genetic predisposition, “dumb luck”, and 
as yet unexplained causes.[3]  
Cancer cells can spread to other parts of the body by two mechanisms: invasion 
and metastasis.  Invasion refers to the direct migration and penetration by cancer cells 
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into neighboring tissues. Metastasis refers to the ability of cancer cells to penetrate into 
lymphatic and blood vessels, circulate through the blood stream, and then invade 
normal tissues elsewhere in the body.[4]  
There are over 60 different organs in the body where a cancer can develop and 
each organ is made up of several different types of cells. For this reason, there are more 
than 200 different types of cancer. Breast cancer, the second leading cause of cancer 
deaths, is the most commonly diagnosed cancer among postmenopausal women.[5]  
In general, breast cancer is classified as estrogen receptor positive breast cancer 
and estrogen receptor negative breast cancer. Roughly one-third of all breast cancer 
patients and two-third of postmenopausal breast cancer patients have estrogen receptor 
positive breast cancer. In this type of breast cancer, cells contain estrogen receptors 
which regulate gene expression as a DNA-binding transcription factor and require 
estrogen to grow and multiply.[6]  
 
1.2. Estrogens 
 
Estrogens are essential regulators of many physiological processes such as 
differentiation and development of reproductive tissues in both men and women, 
protection against osteoporosis via maintenance of bone density, reduction of lipid and 
cholesterol levels in blood acting as a cardioprotective hormone, regulation of 
reproductive behavior, homeostasis and general mood.[7] In addition to normal 
physiological roles of estrogen, the prevalence and progression of cancerous cells 
within the body has been linked to prolonged stimulation by higher than normal levels 
of estrogen.[8] 
 Estrogen receptors are normally in the nucleus. When an estrogen molecule 
enters into target cell by simple diffusion and passes into the nucleus, estrogen receptor 
which exists as monomer complexed with non-steroid-binding heat shock proteins binds 
to estrogen with high affinity and with a high degree of specificity, releasing the heat 
shock proteins. These estrogen-receptor complexes form homodimers, thus the affinity 
of receptors for DNA hormone response elements (HREs) in the regulatory regions of 
estrogen-responsive genes increases. The estrogen-receptor complex binds to DNA 
HREs and recruits coactivator proteins. In this way the target gene is activated to make 
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messenger RNA (mRNA) molecules. These messenger RNAs guide the synthesis of 
specific proteins to increase the cell proliferation.[9]  
Estrogens, the primary female sex hormones, comprise a group of compounds, 
including estrone (1), estradiol (2) and estriol (3). They are the three major naturally 
occurring estrogens in women. Estradiol and estrone are the predominant estrogens 
during reproductive years and menopause, respectively. Estetrol which is another type 
of estrogen is produced only during pregnancy. All of the different forms of estrogen 
are synthesized from androgens. Estrone and estradiol which are the most important 
estrogens in humans are synthesized from androstenedione (4) and testosterone (5), 
respectively, by aromatase which is a unique member of a cytochrome P450 (CYP) 
superfamily of microsomal enzymes. (Figure 1.1) [7]  
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O
O
H
H H
O
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4 5  
Figure 1.1. Estrone (1), estradiol (2), estriol (3), androstenedione (4), and testosterone  
                   (5) structures. 
 
1.3. Aromatase Enzyme 
 
Aromatase, also called estrogen synthetase or estrogen synthase, is an enzyme 
responsible for the last, rate-limiting step in the biosynthesis of estrogens. It is a 
member of the cytochrome P450 superfamily (E.C 1. 14. 14. 1), and is responsible for 
the aromatization of androgens into estrogens. The aromatase enzyme complex which is 
localized in the endoplasmic reticulum of estrogen producing cells is comprised of two 
polypeptides. The first is a specific cytochrome P450 heme protein. The second is a 
flavoprotein, NADPH-cytochrome P450 reductase. This enzyme complex catalyzes 
three consecutive hydroxylation reactions.[4]  
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In humans, the gene CYP19 encodes the aromatase enzyme. It contains nine 
coding exons from II to X. The expression of this gene is regulated by the alternative 
use of eight tissue specific promoters (PI.1, PI.3, PI.4, PI.6, PI.7, and PII) which employ 
different signaling pathways and different transcription factors. For example, as in 
healthy breast tissue aromatase expression is regulated by promoter I.4, in breast cancer 
tissue aromatase expression switches to promoter I.3 and II.[6] [10] 
Aromatase enzyme has become a target for new drug synthesis to treat estrogen 
hormone dependent breast cancer due to its regulatory property in estrogen 
biosynthesis.[11] Approaches for hormonal therapy of estrogen dependent breast 
cancers are either blocking the mechanism of action of estrogens by selective estrogen 
receptor modulators (SERMs) or inhibiting estrogen biosynthesis by aromatase enzyme 
inhibitors (AIs).[4] 
SERMs bind estrogen receptors and change their conformations, thus, simplify 
binding of co-regulatory proteins which activate or suppress transcriptional activation of 
estrogen target genes. SERMs can be properly divided into three main categories: (1) 
triphenylethylene derivatives like tamoxifen (6) (Figure 1.2), (2) other nonsteroidal 
compounds, and (3) steroidal compounds which possess more complete anti-estrogenic 
activity. Tamoxifen, which was approved by the United States Food and Drug 
Administration in 1977, like other SERMs, binds to estrogen receptors of breast cancer 
cells and antagonizes the effect of estrogen on various growth-regulatory genes. The 
dominant effect of tamoxifen is cytostatic with the induction of a G1 cell cycle block by 
slowing cell proliferation.[12] 
 
O
NMe2
6  
Figure 1.2.  Structure of tamoxifen (6).    
 
1.4. Aromatase Inhibitors 
 
Aromatase inhibitors are classified as steroidal and nonsteroidal inhibitors based 
on their structures. Nonsteroidal inhibitors such as letrozole (IC50=2 nM) (7) and 
5 
 
anastrozole (IC50=8 nM) (8) which have the triazole functional group contain a 
heteroatom (usually nitrogen containing heterocyclic moiety) that interacts with the 
heme prosthetic group in the active site of aromatase enzyme and occupy its substrate 
binding site, thus preventing binding of androgens to the active site. (Figure 1.3) 
Heterocyclic moiety may interact with aromatase via hydrogen and/or van der Waals 
bonding. Since the binding is reversible, nonsteroidal inhibitors can be competitively 
displaced from the active site by endogenous substrates. 
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Figure 1.3. Letrozole (7) and anastrozole (8) structures. 
 
                 Steroidal inhibitors such as exemestane (IC50=15 nM) (9) (Figure 1.4) are 
recognized by the active site as an alternative substrate and compete rapidly with natural 
aromatase substrates for the active site of the aromatase enzyme initiating a time 
dependent reactive process resulting in either covalent or very tight binding of the 
inhibitor to the enzyme and causing its inactivation. This irreversible aromatase 
inhibitors are also known as inactivators or “suicide” inhibitors because aromatase is 
inactivated owing to its own mechanism of action.[13] 
 
O
O
9  
Figure 1.4. Structure of exemestane (9). 
 
Besides the large number of synthetic aromatase inhibitors, there is a continuous 
research for natural products to discover new breast cancer chemopreventive agents. 
Flavonoids attract the researchers as a new class of natural products due to their unique 
structures and aromatase inhibitory activities.[14] 
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1.5. Flavanoids 
 
Flavonoids are a group of polyphenolic phytochemical compounds that occur 
ubiquitously in foods of plant origin. Polyphenols possess a basic structure that 
comprises one or more phenolic rings and often have several hydroxyl groups, which 
are highly correlated with their strong antioxidant capacity. Several studies have 
addressed the ability of flavonoids to interfere with the catalytic activity or expression 
of aromatase enzyme. Flavonoids which have considered as phytoestrogens may 
compete with endogenous steroids for enzyme active sites or interact with the estrogen 
receptors.[8] 
 Flavonoids are synthesized from 2'-hydroxy derivative of chalcones (10) 
(Figure 1.5) which are unique in the flavonoid family in lacking a heterocyclic ring and 
possess several biological activities such as estrogenic, antifungal, antibacterial, 
antiviral and anti-inflammatory.[15] Chalcones are also an important class of molecules 
among the currently identified antitumor agents because of being abundant in edible 
plants.[16] 
 
O
10
OH
 
Figure 1.5. Structure of 2'-hydoroxy chalcone (10). 
 
Flavonoids are plant secondary metabolites [17] and are divided into six classes. 
Flavanones (11), flavones (12), and flavanols (13) are the common flavonoids. 
Isoflavonoids (14) which is a distinct class of flavonoids have estrogenic activity. 
Anthocyanins (15) are the charged and colored flavonoids. The last class of flavonoids 
is flavans (16) including catechin (17) and biflavan (18) which are complicated in 
structure and naming. (Figure 1.6) [18] 
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Figure 1.6. Structures of flavanone (11), flavone (12), flavanol (13), isoflavone (14), 
                   anthocyanin (15), flavan (16), catechin (17), and biflavan (18). 
 
1.5.1. Chalcones 
 
Chalcones are cancer preventive food components in a human diet that is rich in 
fruits and vegetables. In literature many chalcone derivatives were synthesized and 
investigated for their possible anticancer activity. As an example, Hsu and colleagues 
examined chalcone (1,3-diphenyl-2-propenone) (10) for its effect on proliferation in 
human breast cancer cell lines, MCF-7 and MDA-MB-231. Their data showed that 
chalcone exhibited significant inhibitory effect with IC50 values of 4.9 µg/mL and 6.0 
µg/mL for MCF-7 and MDA-MB-231cell lines, respectively.[15] 
In another example, a series of novel chalcones and bis-chalcones containing 
boronic acid derivatives were synthesized by Modzelewska and colleagues. Chalcones 
evaluated for their antitumor activity against the human breast cancer MDA-MB-231 
and MCF7 cell lines at low micromolar to nanomolar concentrations. Compound 19 
(Figure 1.7) had the most significant antiproliferative activity with an IC50 value of 0.35 
µM.[16] 
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Figure 1.7. Structure of bischalcone (19). 
 
Lawrence and research group investigated effects of α-substitutions on chalcone 
structure. The cell growth inhibitory properties of the substituted chalcones were 
determined in the K562 human chronic myelogenous leukemia cell line. The chalcones 
20 and 21 (Figure 1.8) with the 3-hydroxy-4-methoxy ring showed the highest 
cytotoxicities with IC50 concentrations of 4.3 nM and 2.1 nM, respectively.[19] 
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Figure 1.8. Structures of substituted chalcones 20 and 21. 
 
Bail and colleagues were evaluated different chalcone derivatives to better 
understand their anti-aromatase activity in human placental microsoms. They also used 
aminoglutethimide (IC50=1.2 µM) as positive control for aromatase inhibition. Results 
show that treatment of human placental microsoms with 2',4',6',4-tetrahydroxychalcone 
(22) and 2',4',6',3,4-pentahydroxychalcone (23) exhibited more anti-aromatase activity 
compared to 2'-hydroxychalcone (24) and 4'-hydroxychalcone (25). (Figure 1.9) Their 
IC50 concentrations was found as 2.6  µM,  2.8 µM, 50 µM, and 30.6 µM, 
respectively.[8] 
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Figure 1.9. Structures of 2',4',6',4-tetrahydroxychalcone (22),  2',4',6',3,4-pentahydroxy- 
                   chalcone (23), 2'-hydroxychalcone (24), and 4'-hydroxychalcone (25). 
 
1.5.2. Flavanones 
 
A set of flavanone and flavone derivatives were synthesized and evaluated for 
their antiproliferative activity against MCF-7 human breast cancer cells by Pouget and 
colleagues. They discussed the structure-activity relationship of these compounds and 
found that unsubstituted flavanone was a weak inhibitor of MCF-7 cell growth as well 
as flavanones with hydroxy group. However, the methoxy group substitution increased 
the antiproliferative activity. On the other hand, flavones showed weak aromatase 
inhibitory effect except 7,8-dihydroxyflavone (26) which was found to be most potent 
(IC50=27.5 µM) whereas 7,8-dihydroxyflavanone (27), the corresponding flavanone, 
was inactive. (Figure 1.10) [20] 
 
O
O
HO
OH
O
O
HO
OH
26 27  
Figure 1.10. Structures of 7,8-dihydroxyflavone (26) and 7,8-dihydroxyflavanone (27). 
 
Fagnere and research team synthesized a series of flavanones by cyclization of 
2'-hydroxy chalcones formed by Claisen-Schmidt condensation and investigated the 
aromatase inhibitory activity. It was observed that the substitution pattern was effective 
on the inhibitory activity. Hydroxyl group at position 3' and/or 4' increased the anti-
aromatase activity; hence, 3',4'-dihydroxy-7-methoxyflavanone (28) (Figure 1.11) 
10 
 
(IC50=2.5 µM) was found more potent than aminoglutethimide (IC50=5.2 µM) which is 
the first aromatase inhibitor clinically used.[21] 
 
O
O
MeO
OH
OH
28  
Figure 1.11. Structure of 3',4'-dihydroxy-7-methoxyflavanone (28). 
 
Yahiaoui and colleagues synthesized new 7,8-benzoflavanones and compared 
them with hydroxy and methoxy substituted flavanones for their anti-aromatase activity. 
They found that 7,8-benzoflavanone (29) was twice more active than 7-
methoxyflavanone (30) with IC50 values of 4.3 µM and 8.0 µM, respectively. They also 
demonstrated that introduction of an electron-donating group such as hydroxyl group 
increased the aromatase inhibitory effect. According to this, 3'-OH substituted 7-
methoxhyflavanone (31) and 7,8-benzoflavanone (32) had more aromatase inhibitory 
activity with IC50 values of 3.5 µM and 0.61 µM, respectively. (Figure 1.12) [22] 
 
O
O
O
O
H3CO
O
O
H3CO
OH
O
O
OH
29 30
31 32  
Figure 1.12. Structures of 7,8-benzoflavanone (29), 7-methoxyflavanone (30),             
                     3'-hydroxy-7-methoxyflavanone (31), 3'-hydroxy-7,8-benzoflavanone (32). 
 
Pouget and research team synthesized (E)- and (Z)-pyridinyl substituted 
flavanone derivatives. These compounds were tested for their cytochrome P450 
aromatase inhibitory effect. It was observed that the presence of a pyridinylmethylene 
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group on flavanone significantly increased aromatase inhibition compared to 
unsubstituted flavanone. It was also showed that the presence of a methoxy group 
increased the aromatase inhibitory activity. IC50 values of (E)-isomers of compounds 33 
and 34 (Figure 1.13) were 0.80 µM and 0.62 µM, respectively. The effect of 
configuration was also investigated and found that (E)-isomers had more anti-aromatase 
activity than (Z)-isomers with IC50 values of 3.3 µM and 1.6 µM, respectively.[23] 
 
O
O
N
R
O
O
N
R
(E) 33, 34-
33: R=H; 34: R=OMe
(Z) 33, 34-
 
Figure 1.13. Structures of compounds (E)-33, 34 and (Z)-33, 34. 
 
1.6. Stilbenes 
 
Stilbenes (1,2-diphenylethylene) are another class of plant secondary 
metabolites.[24] There are two isomeric forms of 1,2-diphenylethylene; (E)-stilbene 
(trans-stilbene) (35), which is not hindered by steric effect, and (Z)-stilbene (cis-
stilbene) (36), which is hindered by steric effect, and therefore less stable. In nature, 
stilbenes overwhelmingly exist in the trans forms.[25] Most stilbenes are derived from 
the trans-resveratrol (37) which can prevent or slow the progression of a wide variety of 
illnesses, including cancer, obesity, senescence, and cardiovascular diseases. (Figure 
1.14) [26] 
 
HO
OH
OH
35 36 37      
Figure 1.14. Structures of (E)-stilbene (35), (Z)-stilbene (36), and trans-resveratrol (37). 
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Murias and colleagues were synthesized five polyhydroxylated resveratrol 
analogues and evaluated for their cytotoxic activity against HL-60 leukemic cells and 
structure-activity relationships. It was demonstrated that resveratrol had higher growth 
inhibitory activity than gallic acid which is a commonly used reference anti-leukemic 
compound (IC50 values: 12.1±0.17 µM and 18.3±0.23 µM respectively). The presence 
of hydroxyl groups on resveratrol increased cytotoxic activity on HL-60 leukemic cells. 
In this study, compound 38 (Figure 1.15), substituted with six hydroxyl groups, was 
found the most active analogue (IC50: 4.2±0.09 µM).[27] 
 
HO
HO
OH
OH
OH
OH
38  
Figure 1.15. Structure of compound 38. 
 
 A group of resveratrol derivatives having chalcone moiety were synthesized and 
tested for their anti-proliferative activity by Ruan and colleagues. It was showed that 
compound 39 (Figure 1.16) had the most potent cytotoxic activity against HepG2 
human liver carcinoma, B16-F10 melanoma, and A549 adenocarcinoma cells with IC50 
values of 0.2 µg/mL, 0.1 µg/mL, and 1.4 µg/mL  respectively.[28] 
  
H3CO
H3CO
O
OCH3
CH3
CH3
39  
Figure 1.16. Structure of compound 39. 
 
Sun and colleagues designed and synthesized a series of new resveratrol 
analogues and evaluated their inhibitory activities against aromatase. Most of the 
resveratrol analogues which had an amino group on the para position of ring A 
consistently showed significant aromatase inhibition activity, with IC50 values in the 
range of 0.59-14.51 µM. When the para-amino group was substituted with nitro, 
13 
 
halogen, hydroxy, nitrile, acetyl, and aminomethyl groups, resulting compounds were 
inactive. Compound 40 (Figure 1.17) which had an IC50 value of 36 nM was the most 
potent aromatase inhibitor. Unsurprisingly, molecular modeling illustrated that one of 
the imidazole nitrogens coordinated with the iron atom of heme prosthetic group, which 
plays a key role in catalytic activity of aromatase.[26] 
 
N
N
OCH3
OCH3
H2N
40  
Figure 1.17. Structure of compound 40. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
 
In this study, it was aimed to investigate the cytotoxic and aromatase inhibition 
properties of previously synthesized simple chalcones (C1-C5), simple stilbenes (S1-
S4), simple flavanones (F1-F3), stilbene-fused chalcones (SC1-SC17) and stilbene-
fused flavanones (SF1-SF17) reported by Akçok et al. (Table 1.1) [29] 
 
Table 1.1. Structures of simple-chalcones C1-C5, simple-stilbenes S1-S4, simple-  
                 flavanones F1-F3, stilbene-fused chalcones SC1-SC17, and stilbene-  
                 fused flavanones SF1-SF17. 
 
OR1
R2
R3 OH
Br
Ar1 H
R''
R'
O
Ar2
O
O
Br
R1
R2
R3
Ar1
O
R''
R'
R1
R2
R3 OH
Ar2Ar1
O
R''
R'
R1
R2
R3 O
Ar2Ar1
C1-C5 S1-S4 F1-F3
SC1-SC17 SF1-SF17  
 
Ar2  
Ar1 
Simple-
Chalcones 
 
Simple-
Flavanones 
 
OMe
   
F  
Simple-
Stilbenes  
  S1 S2 S3 S4 
OH
MeO
 
C1 F1 SC1, SF1 SC2, SF2 SC3, SF3 SC4, SF4 
OH
Cl
 
C2 F2 SC5, SF5 SC6, SF6 SC7, SF7 SC8, SF8 
OH
OMe
 
C3 F3 SC9, SF9 
SC10, 
SF10 
SC11, SF11 
SC12, 
SF12 
OHMeO  
C4
a
  SC13, SF13 
SC14
a
, 
SF14 
SC15
a
; SF15 
SC16
a
, 
SF16 
OHMeO
OMe
 
C5  SC17, SF17    
   a
 could not be purified from starting materials. 
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CHAPTER 2 
 
RESULTS AND DISCUSSION 
 
2.1. Cell Viability Assay 
 
In this study, the anti-proliferative activities of simple-stilbenes, simple-
chalcones, simple-flavanones, and stilbene-fused chalcone and stilbene-fused flavanone 
derivatives were evaluated against MCF-7 and PC-3 cell lines at 50, 40, 30, 20, 10, 1, 
0.5 µM concentrations by using MTT assay.  The amount of formazan (41) crystals 
which are reduced from 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) (42) by mitochondrial dehydrogenase activity in living cells is directly 
proportional the cell number. (Figure 2.1) 
 
N
N
NN
S
N
Br
N
N
N
S
NNH Mitochondrial
Dehydrogenase
42 41  
Figure 2.1. Conversion of 3-(4,5-dimethylthiazol-2-yl)-2 5-diphenyl tetrazolium bromide 
                  (MTT) (42) to formazan (41) crystals. 
 
The absorbance of formazan crystals was determined at 540 nm. IC50 values of 
cytotoxic compounds were calculated by nonlinear regression analysis of at least three 
separate triplicate experiments. Results of MTT assay were summarized in Tables 2.1-
2.7. 
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Table 2.1. Calculated IC50 values (µM) of simple-stilbenes S1-S4 for cytotoxic activity 
                  on PC-3 and MCF-7 cell lines. 
 
H
R''
R'
O
Ar2
 
 
Ar2 
OMe
  
 
F
 
Simple-stilbenes S1 S2 S3 S4 
PC-3 _b _b _b _b 
MCF-7 _b _b _b _b 
       b 
not active for all tested concentrations. 
 
 
 
Table 2.2. Calculated IC50 values (µM) of simple-chalcones C1-C5 for cytotoxic  
                  on PC-3 and MCF-7 cell lines. 
 
OR1
R2
R3 OH
Br
Ar1
 
 
Ar1 
OH
MeO
 
OH
Cl
 OH
OMe
 
OHMeO
 
OHMeO
OMe
 
Simple-chalcones 
 
C1 C2 C3 C4
a
 C5 
PC-3 33 27 3 nt 10 
MCF-7 31 11 7 nt 6 
   a
 could not be purified from starting materials, nt not tested 
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Table 2.3. Calculated IC50 values (µM) of simple-flavanones F1-F3 for cytotoxic 
                  activity on PC-3 and MCF-7 cell lines. 
 
O
O
Br
R1
R2
R3
Ar1
 
 
Ar1 
MeO
O
 
Cl
O
 O
OMe
 
Simple-flavanones F1 F2 F3 
PC-3 21 23 17 
MCF-7 20 14 17 
 
 
 
Table 2.4. Calculated IC50 values (µM) of stilbene-fused chalcones SC1-SC17 for  
                  cytotoxic activity on PC-3 cell line. 
 
O
R''
R'
R1
R2
R3 OH
Ar2Ar1
 
Ar2  
Ar1  
OMe
  
 
F
 
OH
MeO
 
15 12 12 11 
OH
Cl
 
25 26 22 23 
OH
OMe
 
12 12 16 8 
OHMeO  
_b nt nt nt 
OHMeO
OMe
 
_b    
    b 
not active for all tested concentrations, nt not tested 
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Table 2.5. Calculated IC50 values (µM) of stilbene-fused chalcones SC1-SC17 for  
                  cytotoxic activity on MCF-7 cell line. 
 
O
R''
R'
R1
R2
R3 OH
Ar2Ar1
 
     Ar2  
     Ar1    
OMe
 
 
 
F
 
OH
MeO
 
7 21 25 19 
OH
Cl
 
21 23 27 20 
OH
OMe
 
13 16 37 26 
OHMeO  
_b nt nt nt 
OHMeO
OMe
 
_b    
      b 
not active for all tested concentrations, nt not tested 
 
Table 2.6. Calculated IC50 values (µM) of stilbene-fused flavanones SF1-SF17 for  
                  cytotoxic activity on PC-3 cell line. 
 
O
R''
R'
R1
R2
R3 O
Ar2Ar1
 
   Ar2 
  Ar1 
OMe
   
F
 
  
MeO
O  
_b _b _b _b 
  
Cl
O  
_b _b _b _b 
     O
OMe
 
_b 9 22 _b 
OMeO  
_b _b _b _b 
OMeO
OMe
 
_b    
          b 
not active for all tested concentrations. 
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Table 2.7. Calculated IC50 values (µM) of stilbene-fused flavanones SF1-SF17 for  
                  cytotoxic activity on MCF-7 cell line. 
 
O
R''
R'
R1
R2
R3 O
Ar2Ar1
 
   Ar2 
  Ar1 
OMe
   
F
 
  
MeO
O  
_b _b _b _b 
   
Cl
O  
_b _b _b _b 
       O
OMe
 
_b 21 35 _b 
OMeO  
_b _b _b _b 
OMeO
OMe
 
_b    
      b 
not active for all tested concentrations. 
 
In this study, 42 compounds which were synthesized previously were tested for 
their cytotoxic activity. For this purpose the breast cancer cell line (MCF-7) and the 
prostate cancer cell line (PC-3) were used since both cell lines were hormone-dependent 
cancer cell lines. 
When the compounds were classified for their cytotoxic properties it was seen 
that no simple-stilbene and stilbene-fused flavanone, except SF10 and SF11, had 
cytotoxic activity against MCF-7 and PC-3 cells at tested concentrations. However, 
simple-chalcones, simple-flavanones, and stilbene-fused chalcones have cytotoxic 
activity. 
When the structures of simple-chalcones were compared it was seen that 
although the simple chalcones C1 and C3 had the same substituent (methoxy group) at 
different positions on their Ar1 rings their cytotoxic properties were fairly different. 
While the simple-chalcone C3 had IC50 concentrations of 7 µM and 3 µM, the simple-
chalcone C1 had IC50 concentrations of 31 µM and 33 µM against MCF-7 and PC-3 
cells, respectively. It seems the position of methoxy substituent on Ar1 ring plays an 
important role especially methoxy substitution at 6' position of Ar1 ring increases the 
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cytotoxic activity. A similar result was observed for the simple chalcone C5 which had 
the comparable cytotoxic activity with that of C3.  
When the structure-activity relationships of stilbene-fused chalcones were 
discussed it was seen that when the simple-chalcone C1 was fused with stilbene 
structures their cytotoxic activities increased against both cell lines. Especially, the 
stilbene-fused chalcone SC1 was more than four times cytotoxic against MCF-7 cells 
with an IC50 value of 7 µM compare to simple-chalcone C1 with an IC50 value of 31 
µM. 
On the other hand, when the simple-chalcone C2 was fused with stilbene-
structures, the cytotoxic activity against PC-3 cells did not change while the cytotoxic 
activity against MCF-7 cells increased two times compare to simple one. 
In addition, the fusion of simple-chalcone C3 with stilbene structures decreased 
the cytotoxic activity against both cell lines. Nevertheless, all of the tested stilbene-
fused chalcones, except SC13 and SC17, had cytotoxic activity. 
When the structures of simple-flavanones were compared; it was seen that the 
simple-flavanone F3 with a methoxy substituent at position 5 was more effective than 
the simple-flavanone F1 with a methoxy substituent at position 6. On the other hand, 
while the simple-flavanone F2 with chlorine substituent was more cytotoxic against 
MCF-7 cells it was less cytotoxic against PC-3 cells compare to other simple-
flavanones. 
The stilbene-fused flavanones did not show any cytotoxic activity at all (except 
SF10 and SF11) while the simple-flavanones were cytotoxic. Therefore, it is clear that 
stilbene fusion on simple-flavanones somehow was causing the loss of cytotoxic 
activity. It seems the stilbene-fused flavanones mimic the stilbene structures. In 
addition, when the structures of cytotoxic stilbene-fused flavanones, SF10 and SF11, 
were thought; interestingly there is a methoxy substituent at the same position with the 
that of the most cytotoxic simple flavanone F3 and simple chalcones C3 and C5. 
Despite of this similarity it seems this is not the only requirement for a strong cytotoxic 
activity because there are two stilbene-fused flavanones having same substituent at ring 
Ar1 but do not have cytotoxic activity SF9 and SF12. Hence the substituent type at 
stilbene part of the molecule can also play an important role and it seems that existence 
of a nonpolar substituent at stilbene can be a good choice for increased cytotoxic 
activity. The stilbene-fused flavanone SF10 with methyl substituent at para position was 
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more cytotoxic with IC50 concentrations of 9 µM and 21 µM against PC-3 and MCF-7 
cells, respectively. 
 
2.2. Aromatase Inhibition 
 
In this study, in addition to cytotoxic activity, simple and fused compounds were 
tested for possible aromatase inhibition properties by CYP19/MFC High Throughput 
Inhibitor Screening Kit. The conversion of 7-methoxy-4-trifloromethyl coumarin 
(MFC) (43) substrate into fluorescent 7-hydroxy-4-trifloromethyl coumarin (HFC) (44) 
product was measured in the presence of different concentrations of tested compounds. 
(Figure 2.2) The intensity of the fluorescence of HFC is proportional the aromatase 
activity. IC50 values were calculated by nonlinear regression analysis of at least two 
separate experiments by “GraphPad Prism 5” software. Aromatase inhibitor 
ketoconazole (45) was used as positive control. (Figure 2.3) Results were summarized 
in Tables 2.8-2.12.              
 
OH3CO
CF3
O OHO
CF3
O
 Aromatase
43 44  
Figure 2.2. 7-Methoxy-4-trifloromethyl coumarin (43) is converted to 7-hydroxy-4- 
                   trifloromethyl coumarin (44) by aromatase activity. 
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N
H
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O
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Figure 2.3. Structure of ketoconazole (45). 
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Ketoconazole was tested at 40.00, 13.33, 4.44, 1.48, 0.49, 0.165, 0.055, and 
0.018 µM concentrations. Its IC50 value was calculated as 2 µM. (Figure 2.4) 
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Figure 2.4. Dose dependent aromatase inhibition activity of ketoconazole (45). 
 
 
 
Table 2.8. Calculated IC50 values (µM) of simple-stilbenes S1-S4 for aromatase 
                  inhibition. 
 
H
R''
R'
OH
Ar2
 
 
Ar2 
OMe
  
 
F
 
Simple-stilbenes S1 S2 S3 S4 
CYP19 7 _b 65 _b 
        b 
not active for all tested concentrations 
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Table 2.9. Calculated IC50 values (µM) of simple-chalcones C1-C5 for aromatase 
                  inhibition. 
 
OR1
R2
R3 OH
Br
Ar1
 
 
Ar1 
OH
MeO
 
OH
Cl
 OH
OMe
 
OHMeO
 
OHMeO
OMe
 
Simple-chalcones 
 
C1 C2 C3 C4
a
 C5 
CYP19 39 >300 >300 nt >300 
     a
 could not be purified from starting materials, nt not tested 
 
 
 
Table 2.10. Calculated IC50 values (µM) of simple-flavanones F1-F3 for aromatase 
                    inhibition. 
 
O
O
Br
R1
R2
R3
Ar1
 
 
Ar1 
MeO
O
 
Cl
O
 O
OMe
 
Simple-flavanones F1 F2 F3 
CYP19 _b 122 _b 
            b 
not active for all tested concentrations. 
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Table 2.11. Calculated IC50 values (µM) of stilbene-fused chalcones SC1-SC17 for 
                    aromatase inhibition. 
 
O
R''
R'
R1
R2
R3 OH
Ar2Ar1
 
 
     Ar2  
     Ar1    
OMe
 
 
 
F
 
OH
MeO
 
_b 223 >300 >300 
OH
Cl
 
_c >300 >300 _b 
OH
OMe
 
_b >300 >300 _b 
OHMeO  
_c nt nt nt 
OHMeO
OMe
 
_b    
       b 
not active for all tested concentrations, 
c
 gave higher fluorescent intensity compared to negative  
     control, nt not tested. 
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Table 2.12. Calculated IC50 values (µM) of stilbene-fused flavanones SF1-SF17 for 
                   aromatase inhibition. 
 
O
R''
R'
R1
R2
R3 O
Ar2Ar1
 
 
   Ar2 
  Ar1 
OMe
   
F
 
MeO
O  
_c _c _b _c 
Cl
O  
34 _c _b >300 
O
OMe
 
_c _b _b _b 
OMeO  
>300 >300 39 >300 
OMeO
OMe
 
_c    
     b 
not active for all tested concentrations, 
c
 gave higher fluorescent intensity compared to negative 
     control, nt not tested. 
 
In this study, 42 compounds were tested for their aromatase inhibition activity. 
However, while twenty of them had anti-aromatase activity only seven of the twenty 
compounds (S1, S3, C1, SC2, F2, SF5 and SF15) had significant activity with IC50 
concentrations of less than 300 µM. Moreover, three of the seven compounds (C1, F2 
and SC2) also had cytotoxic activity at the same time. 
Actually, there was not a common property in the structures of compounds 
which had anti-aromatase activity. Among these active compounds there were two 
simple-stilbene, one simple-chalcone, one simple-flavanone, one stilbene-fused 
chalcone, and two stilbene-fused flavanones.  
When the structures of active simple-stilbenes were compared it was seen that 
while one simple-stilbene S1 had a methoxy group the other one (S3) had a methyl 
group on their Ar2 rings. The simple-stilbene S1 which was substituted a methoxy group 
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was the most active compound with IC50 concentration of 7 µM for aromatase 
inhibition. 
When the structures of simple-chalcone C1 and stilbene-fused chalcone SC2 
were compared it was seen that these two compounds had the same methoxy group on 
their Ar1 ring. However, it was clear that the fusion of chalcone structure with stilbene 
decreased the aromatase inhibitory activity more than five times. While simple-chalcone 
C1 had IC50 concentration of 39 µM the stilbene-fused chalcone SC2 had IC50 
concentration of 223 µM for aromatase inhibition. 
When the structures of simple-flavanone F2 and stilbene-fused flavanone SF5 
were compared it was seen that they had the same Ar1 ring with chlorine (Cl) 
substituent. However, IC50 concentrations of these compounds indicated that the fusion 
of flavanone structure with the stilbene increased the aromatase inhibition activity more 
than three times. The simple-flavanone F2 had IC50 concentration of 122 µM and the 
stilbene-fused flavanone SF5 had IC50 concentration of 34 µM for aromatase inhibition. 
In addition, the other active flavanone SF15 had a stilbene-fused structure with IC50 
value of 39 µM. 
In this study it was aimed to investigate the compounds which possessed both 
cytotoxic activity and aromatase inhibition activity simultaneously. However, while 
twelve of the tested compounds had two activities at the same time only three of the 
twelve compounds (C1, SC2 and F2) were significantly active. While these three 
compounds had average cytotoxic activities with IC50 concentrations between 12 and 33 
µM the simple-chalcone C1 had significant aromatase inhibition activity with IC50 
concentration of 39 µM compare to other two compounds (F2 and SC2) with IC50 
concentrations of 122 µM and 223 µM, respectively. 
The results were evaluated in two perspectives. The first one is the potential of 
hybrid system to carry more than one biological activity. In this perspective molecules 
were divided into four different subgroups. Accordingly the first group shows both 
cytotoxic and aromatase inhibitory activities. These molecules are C1, C5, F2, SC2, 
SC3, SC4, SC6, SC7, SC10, and SC11. The second group which exhibits only 
cytotoxic activity contains C2, C3, SC1, SC5, SC8, SC9, SC12, F2, F3, SF10, and 
SF11. In the third group there are compounds S1, S3, SF5, SF8, SF13, SF14, SF15, and 
SF16 which have only aromatase inhibitory activities. The compounds in the fourth 
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group are S2, S4, SC13, SC17, SF1-SF4, SF6, SF7, SF9, SF12, and SF17 which 
possess neither cytotoxicity nor aromatase inhibitory activity.  
Although among the all test compounds only simple and stilbene-fused 
chalcones can carry two biological activities simultaneously and their aromatase 
inhibition properties only can be seen at above 300 µM concentrations. Conversely 
stilbene-fused flavanones cannot carry out cytotoxic and aromatase inhibition activities 
at the same time. There is only one compound (C1) which possess both cytotoxic and 
aromatase inhibitory activity at below 100 µM concentrations.  
The second perspective is the mimicking performance of the fused system 
compared to simple ones. In aromatase inhibition experiments two of the simple-
stilbenes S1 and S3 showed significant activity at lower µM concentrations (IC50=7 µM, 
65 µM respectively) without any cytotoxic activity. Conversely all of the simple-
chalcones have cytotoxic activity at lower µM concentrations, however only the simple-
chalcone C1 inhibits aromatase significantly with IC50 value of 39 µM. In addition, two 
of the simple-flavanones (F1 and F3) have not aromatase inhibitory activity although 
they are cytotoxic at lower µM concentrations. Only the simple-flavanone F2 possesses 
two biological activities at the same time; however its aromatase inhibition 
concentration is above 100 µM. According to these results when the hybrid compounds 
are compared for their mimicking performances it was seen that stilbene-fused 
chalcones are mimicking only simple-chalcones rather than simple-stilbenes. On the 
other hand stilbene-fused flavanones have potency to show more than one trend because 
most of the stilbene-fused flavanones can mimic neither simple-flavanones nor simple-
stilbenes depending on the substitution. Contrarily the fusion of stilbene structure to 
flavanone causes the missing of cytotoxic and aromatase inhibitory activities. 
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2.3. Apoptosis Analysis 
 
Apoptosis, which is the process of programmed cell death in a normal cell 
growth, is characterized by exact morphologic properties. One of the earliest features is 
the loss of plasma membrane asymmetry. As in normal cells the membrane 
phospholipid phosphatidylserine (PS) is located inner side of the plasma membrane, in 
apoptotic cells it is translocated to the outer side of the plasma membrane. Annexin V-
FITC Screening Kit was used in order to investigate the apoptotic effects of selected test 
compounds (C3, F2, SC2 and SF10) on MCF-7 and PC-3 cancer cell lines. Annexin V, 
which is a Ca
2+
 dependent phospholipid-binding protein, has a great affinity for 
phospholipid phosphatidylserine (PS). When Annexin V is conjugated to fluorescein 
isothiocyanate (FITC), which is a fluorochrome, serves as a sensitive probe for flow 
cytometric analysis of apoptotic cells. Annexin V-FITC staining can recognize 
apoptosis at an earlier stage because externalization of phospholipid phosphatidylserine 
(PS) occurs in the earlier stage of apoptosis. In addition to Annexin V-FITC, propidium 
iodide (PI) was used to distinguish viable from nonviable cells. Propidium iodide is an 
intercalator and only the membranes of dead and damaged cells are permeable to it. If 
cells are undergoing apoptosis they stain positive for Annexin V-FITC and negative for 
PI. If cells stain positive for both  Annexin V-FITC and PI they are either in the end 
stage of apoptosis, and are undergoing necrosis, or are already dead. Cells which stain 
negative for both Annexin V-FITC and PI are alive, and they are not undergoing 
apoptosis.[30] 
The selected compounds (C3, F2, SC2 and SF10) were analyzed for their dose-
dependent apoptotic effects, since earlier studies have showed that a 48 hours exposure 
to the selected compounds reduced the viability of breast cancer cells (MCF-7) and 
prostate cancer cells (PC-3). Results were summarized in Figures 2.11-2.18.  
The IC50 value of simple-chalcone C3 was found 7 µM against MCF-7 cell line 
and 3 µM against PC-3 cell line by MTT assay. Results of apoptosis analysis also 
showed that while simple-chalcone C3 decreased the percentage of live cells more than 
50% at concentrations 10 µM and 20 µM in both MCF-7 and PC-3 cell lines, it 
increased the percentage of apoptotic cells. (Figure 2.5-2.6) 
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Figure 2.5. Apoptotic effect of simple chalcone C3 on MCF-7 cells. 
 
 
 
 
Figure 2.6. Apoptotic effect of simple chalcone C3 on PC-3 cells. 
 
The simple-flavanone F2, which had IC50 values of 14 µM and 23 µM against 
MCF-7 and PC-3 cell lines, respectively, increased the percentage of apoptotic cells in 
MCF-7 cells by 20% at 20 µM compare to control, however F2 was ineffective against 
PC-3 cells. (Figure 2.7-2.8) 
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Figure 2.7. Apoptotic effect of simple flavanone F2 on MCF-7 cells. 
 
 
 
Figure 2.8. Apoptotic effect of simple flavanone F2 on PC-3 cells. 
 
The stilbene-fused chalcone SC2 had cytotoxic activity against MCF-7 and PC-3 
cancer cells with IC50 values of 21 µM and 12 µM, respectively. Results of apoptosis 
analysis showed that compound SC2 can induce apoptosis on PC-3 cells than MCF-7 
cells. SC2 caused late apoptosis by 26% and necrosis by 24% in PC-3 cells at 20 µM; 
however, it was nearly ineffective at 10 µM and lower concentrations against PC-3 
cells. On the other hand, SC2 did not show significant apoptotic effect even at 20 µM 
although it had IC50 value of 21 µM against MCF-7 cells. (Figure 2.9-2.10) 
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Figure 2.9. Apoptotic effect of stilbene-fused chalcone SC2 on MCF-7 cells.  
 
 
 
Figure 2.10. Apoptotic effect of stilbene-fused chalcone SC2 on PC-3 cells.  
 
The stilbene-fused flavanone SF10 reduced the percentage of live cells by only 
10% at 20 µM although it had 21 µM IC50 concentration against MCF-7 cells while it 
increased the percentage of apoptotic cells by 6% and 8% at 20 µM and 10 µM, 
respectively. In contrast to the behavior against MCF-7 cells, SF10, which had 9 µM 
IC50 value against PC-3 cells, decreased the percentage of live cells by 63% and 39% 
and increased the percentage of apoptotic cells by 53% and 32% in PC-3 cells at 20 µM 
and 10 µM, respectively. (Figure 2.11-2.12) 
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Figure 2.11. Apoptotic effect of stilbene-fused flavanone SF10 on MCF-7 cells. 
 
 
 
Figure 2.12. Apoptotic effect of stilbene-fused flavanone SF10 on PC-3 cells. 
 
2.4. Cell Cycle Analysis 
 
The cell cycle has two major phases: interphase and mitosis. In mitosis, the 
mitotic phase, the mother cell divides into two genetically identical daughter cells. 
Interphase which is the phase between mitotic events has three distinct, successive 
stages. During the first stage which is called G1, cells monitor their environment, and 
synthesize RNA and proteins to induce growth when the requisite signals are received. 
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Cells enter the S phase when conditions are right and carry out to DNA synthesis and 
replicate their chromosomal DNA. In the G2 phase, which is the final stage of the 
interphase, cells continue to grow and prepare for mitosis. 
 To investigate the effects of selected compounds (C3, F2, SC2 and SF10) on the 
cell cycle of MCF-7 and PC-3 cancer cell lines cell cycle was analyzed by propidium 
iodide staining which is utilized as the DNA fluorochrome and requires blue light as the 
excitation source. The fluorescence intensity of the stained cells is correlated with the 
amount of cellular DNA content; however propidium iodide also stains double-stranded 
RNA. In order to prevent the interference of double-stranded RNA RNase A is added to 
the staining solution. This method provides the percentage of cells in G1, S, and G2/M 
phases.[31]  
 The dose-dependent effects on cell cycle parameters of breast cancer cells 
(MCF-7) and prostate cancer cells (PC-3) after exposure to selected compounds (C3, 
F2, SC2 and SF10) were investigated by flow cytometer, since cell viability studies 
have demonstrated that a 48 hours exposure to these selected compounds (C3, F2, SC2 
and SF10) reduced the viability of MCF-7 and PC-3 cells. 
 Cells incubated with different concentrations (0.1 µM, 1 µM, 10 µM, and 20 
µM) of these selected compounds for 48 hours were examined for their distribution in 
G1, S, and G2 phases of the cell cycle. Results were summarized in Figures 2.19-2.26.  
The simple-chalcone C3 did not significantly change the amount of cells in G2 
phase; however the cell composition in G1 phase decreased by 15% and the cell 
composition in S phase increased by 12% at 10 µM in MCF-7 cells. On the other hand, 
in PC-3 cells C3 decreased the percentage of cells in G1 phase by 26% and increased 
the percentage of cells in S phase by 14% at 20 µM. C3 also increased the cell 
composition in G2 phase by 12% at 20 µM compare to control. (Figure 2.13-2.14) 
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Figure 2.13. Effect of simple-chalcone C3 on cell cycle in MCF-7 cells. 
 
 
 
 
Figure 2.14. Effect of simple-chalcone C3 on cell cycle in PC-3 cells. 
 
The treatment with simple-flavanone F2 caused a little change in the cell cycle 
distribution of MCF-7 cells, but it had no effect on the cell cycle distribution of PC-3 
cells. (Figure 2.15-2.16) 
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Figure 2.15. Effect of simple-flavanone F2 on cell cycle in MCF-7 cells. 
 
 
 
Figure 2.16. Effect of simple-flavanone F2 on cell cycle in PC-3 cells. 
 
The stilbene-fused chalcone SC2 increased the percentage of cells in G1 phase 
and decreased the percentage of cells in S phase in MCF-7 cells at 10 µM and 20 µM 
concentrations. There was not considerable change in the G2 phase of MCF-7 cells. 
However, while the stilbene-fused chalcone SC2 decreased the cell composition in G1 
phase by 21% and in G2 phase by 5%, it increased the cell composition in S phase by 
26% in PC-3 cells at 20 µM concentration. (Figure 2.17-2.18) 
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Figure 2.17. Effect of stilbene-fused chalcone SC2 on cell cycle in MCF-7 cells. 
 
 
Figure 2.18. Effect of stilbene-fused chalcone SC2 on cell cycle in PC-3 cells. 
 
The stilbene-fused flavanone SF10 decreased the percentage of cells in S phase 
by 10% and increased the percentage of cells in G2 phase by 13% at 20 µM in MCF-7 
cells, while it was ineffective on G1 phase. SF10 at 1 µM and lower concentrations were 
nearly ineffective on MCF-7 cell cycle distribution. However, while SF10 decreased the 
cell composition in G1 phase by 24% and increased the cell composition in S phase by 
30% at 20 µM, it changed the amount of cells in G2 phase by only 5% in PC-3 cells. 
(Figure 2.19-2.20) 
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Figure 2.19. Effect of stilbene-fused flavanone SF10 on cell cycle in MCF-7 cells. 
 
 
 
Figure 2.20. Effect of stilbene-fused flavanone SF10 on cell cycle in PC-3 cells. 
 
In this study, the most cytotoxic compound was simple-chalcone C3 with IC50 
value of 7 µM and 3 µM against breast cancer cells (MCF-7) and prostate cancer cells 
(PC-3), respectively. Additionally, the results of apoptosis analysis were compatible 
with IC50 concentrations. Results indicated that in both cell lines simple-chalcone C3 
decreased the percentage of viable cells by more than 50% at 10 µM and 20 µM. At 
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these concentrations both MCF-7 cells and PC-3 cells went to apoptosis; however 
simple-chalcone C3 was ineffective on both cell lines at 1 µM and lower 
concentrations. 
In addition, the results of cell cycle analysis showed that the percentage of cells 
in G1 phase decreased and the percentage of cells in S phase increased in MCF-7 cells at 
higher C3 concentrations especially at 10 µM. However, in the percentage of cells in G2 
phase did not change significantly. The simple chalcone C3 caused the accumulation of 
cells in S phase at higher concentrations. In this case, C3 might be cytotoxic during 
DNA synthesis.  
On the other hand, the same compound C3 caused the accumulation of PC-3 
cells in S and G2 phases while the percentage of PC-3 cells in G1 phase decreased at 20 
µM. The possible reason of the accumulation in G2 phase might be blocking the 
formation of mitotic spindles. C3 might be effective on tubulin polymerization.  
The stilbene-fused chalcone SC2 was the only compound which possessed both 
cytotoxic activity and aromatase inhibitory activity among the stilbene-fused chalcones. 
Its IC50 concentration was 12 µM against PC-3 cell line; however, it decreased the 
percentage of viable cells by 58% at 20 µM. At this concentration SC2 caused the 26% 
of cells to go apoptosis and 24% of cells to go necrosis. But SC2 was ineffective at 10 
µM and lower concentrations. On the other hand, while the stilbene-fused chalcone SC2 
had an IC50 value of 21 µM against MCF-7 cells, it did not have apoptotic effect on 
MCF-7 cells. 
The results of cell cycle analysis exhibited that in PC-3 cell line while SC2 
decreased the percentage of cells in G1 and G2 phases, it increased the percentage of 
cells in S phase. The accumulation in S phase indicated that SC2 might be cytotoxic 
during DNA synthesis. In MCF-7 cells, SC2 decreased the percentage of cells in G1 
phase by 17% and increased the percentage of cells in S phase and G2 phase by 12% 
and 6% respectively. 
The stilbene-fused flavanone SF10 was one of two stilbene-fused flavanones 
which had cytotoxic activity against MCF-7 and PC-3 cells. It had cytotoxic activity 
against both cell lines at lower concentrations compare to other cytotoxic stilbene-fused 
flavanone SF11.  
SF10 which had IC50 concentration of 9 µM against PC-3 cell line decreased the 
percentage of viable cells by 39% at 10 µM and 63% at 20 µM. While SF10 caused the 
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cells to go apoptosis at higher concentrations it was ineffective at lower concentrations 
in PC-3 cells. On the other hand, in MCF-7 cells SF10 decreased the percentage of live 
cells by only 10%. 
According to the results of cell cycle analysis, SF10 caused the accumulation of 
PC-3 cells in S phase. In contrast, SF10 increased the percentage of MCF-7 cells in G2 
phase at higher concentrations. SF10 might be effective on DNA synthesis and tubulin 
polymerization in PC-3 and MCF-7 cells, respectively. 
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CHAPTER 3 
 
EXPERIMENTAL 
 
3.1. Cell Viability Assay (MTT Test) 
 
The human prostate cancer (PC-3) cell line was provided by Professor Doctor 
Kemal Sami Korkmaz (Ege University, Engineering Faculty, Department of 
Bioengineering), human breast cancer (MCF-7) cell line was obtained from Assistant 
Professor Oğuz Bayraktar (İzmir Institute of Technology, Department of Engineering, 
Chemical Engineering). The breast cancer cells were grown in Roswell Park Memorial 
Institute-1640 (RPMI-1640) supplemented with 10% fetal bovine serum (FBS) and 1% 
gentamycin sulphate (50 mg/mL), prostate cancer cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 5%  fetal bovine serum (FBS) 
and 1% gentamycin sulphate (50 mg/mL) in 5%  CO2 humidified incubator at 37 °C. 
Cells were passaged when they reached 80-85% confluence.  The passage number range 
for both cell lines was maintained between 10 and 20.  
In order to investigate the cytotoxic activity of test compounds, 95 µL of cell 
suspension was inoculated into 96-well microculture plates at 1x10
4
 cells density per 
well in culture media containing FBS, and gentamycin sulphate. Cells were incubated 
for 24 h to attach to wells before treatment with test compounds. The test compounds 
were dissolved in dimethyl sulfoxide (DMSO) (Sigma, USA), filter sterilized, diluted at 
appropriate concentrations with the culture medium. After 24 h, 5 µL of diluted 
compounds were added to cells to maintain final concentrations 50, 40, 30, 20, 10, 1 
µM and 500 nM for triplicate assay. In all wells, 1% DMSO final concentration was 
fixed. Cells treated with test compounds were incubated further for 48 h in CO2 
incubator at 37 °C. After the incubation, the medium was poured out and cell 
monolayers were washed with phosphate-buffered saline (PBS) to remove any trace of 
compounds and to prevent color interference while optical density determination. The 
stock solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
(Sigma, USA) was made in PBS to obtain a concentration of 5 mg/mL. %10 MTT 
solutions were prepared with DMEM and RPMI for prostate and breast cancer cells, 
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respectively. 100 µL of diluted MTT solution was added to each well and plates were 
incubated at 37 °C for 4 h in dark. After 4 hours, plates were centrifuged at 1800 rpm 
for 10 minutes at room temperature to avoid accidental removal of formazan crystals. 
MTT solution was removed and 100 µL DMSO was added to each well to dissolve the 
formazan crystals. The absorbance at 540 nm was determined on a plate reader. Each 
compound was assayed three times in triplicate. IC50 values of compounds were 
calculated by nonlinear regression analysis of these three separate triplicate experiments 
by “GraphPad Prism 5” software.[32] [33] 
 
3.2. Aromatase Inhibition Assay 
 
Inhibitory activity of compounds on aromatase was evaluated in vitro using 
CYP19/MFC high-throughput screening kit (BD Biosciences, Oxford, UK) according to 
the manufacturer’s protocol. Ketoconazole was used as positive control and 7-methoxy-
trifluoromethylcoumarin (MFC) was used as substrate. In this fluorescence-based assay 
it was measured the conversion rate of the non-fluorescent MFC substrate into 
fluorescence product 7-hydroxy-4-trifluoromethyl coumarin (HFC). Test compounds 
were dissolved in acetonitrile. Each compound was diluted in NADPH-cofactor mix 
(1.13 mL of Cofactors, 0.9 mL of G6PDH, 0.6 mL of Control Protein, 87.4 mL of 37°C 
water) for seven different concentrations (1200.00, 400.00, 133.33, 44.44, 14.81, 4.94, 
1.65, and 0.55 µM) and placed in duplicate on a 96-well plate. The plate was then 
incubated at 37 °C for 10 minutes. After incubation, 100 μL of the enzyme/substrate 
mix (pre-warmed phosphate buffer (0.5 M, pH 7.4), 70.5 mL of 37°C water, 1.35 mL of 
HTS-760, and 180 µL of 25 mM MFC.) was added to the treated conditions and the 
plate was then incubated at 37 °C for 30 minutes. Concentrations of CYP19 and 
substrate were fixed to 7.5 nM and 25 µM respectively. After incubation, 75 μL of Stop 
Reagent (Tris Base, 0.5 M) was added to the entire plate and 100 μL of the 
enzyme/substrate mix was added in the non-treated blank columns. Background 
fluorescence which was observed from blank columns was subtracted from the 
fluorescence of the all reactions to find the fluorescence emitted only from HFC 
products. Fluorescence of HFC was detected by employing an excitation wavelength of 
405 nm and emission wavelength of 520 nm. IC50 values for potential aromatase 
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inhibitors were calculated by nonlinear regression analysis of at least two separate 
experiments by “GraphPad Prism 5” software. 
 
3.3. Apoptosis Analysis  
 
In order to investigate the apoptotic effects of test compounds against breast 
cancer cells (MCF-7) and prostate cancer cells (PC-3) the selected compounds (C3, F2, 
SC2 and SF10) were tested by using Annexin V- FITC Detection Kit. Cells were 
inoculated into 6-well plates and incubated in CO2 incubator at 37 °C. After 24 hours 20 
µL of test compounds, dissolved in DMSO, were added to incubated cells at final 
volume of 2 mL and final concentrations of 20, 10, 1, 0.1 µM. The treated cells were 
incubated for 48 hours in CO2 incubator at 37 °C. After incubation, cells were harvested 
by trypsin and centrifuged at 800 rpm for 5 minutes. The pellet was dissolved in 5 ml of 
PBS and centrifuged again. The pellet was resuspended in 200 µL of binding buffer. 2 
µL of Annexin V-FITC and 2 µL of PI were added. The stained cells were incubated for 
15 minutes at room temperature. After incubation the apoptotic effects of test 
compounds were determined by flow cytometer.[34] 
 
3.4. Cell Cycle Analysis 
 
To investigate the effects of the selected compounds (C3, F2, SC2 and SF10) on 
the cell cycle the most cytotoxic compounds were tested in breast cancer cell line 
(MCF-7) and prostate cancer cell line (PC-3) by propidium iodide staining. Into 6-well 
plates 1980 µL of cell suspension at a density of 5 x 10
5
 cells per well were inoculated, 
and incubated for 24 hours. Test compounds were dissolved in DMSO and added to 
incubated cells to maintain the final concentrations of 20, 10, 1, and 0.1 µM. The cells 
treated with test compounds were incubated for 48 hours in CO2 incubator at 37 °C. 
After incubation cells were harvested by trypsin and centrifuged at 1200 rpm for 10 
minutes. The supernatant was poured and pellet was dissolved in 5 mL of PBS. The cell 
suspension was centrifuged again. The pellet was resuspended in 1 mL cold PBS and 
fixed by adding 4 mL of -20 °C ethanol (99.8%) on low speed vortex. The fixed cells at 
least 24 hours were incubated at -20 °C. After incubation fixed cell suspension was 
43 
 
centrifuged at 1200 rpm for 10 minutes at 4 °C. The pellet was dissolved in 5 mL of 
PBS and centrifuged again. The pellet was resuspended in 200 µL phosphate buffer 
including 0.1% Triton X-100. 20 µL RNase A (200 µg/mL) was added to cell 
suspension and cells were incubated in CO2 incubator at 37 °C for 30 minutes. After 
incubation 20 µL PI (1 mg/mL) was added and cells were incubated at room 
temperature for 15 minutes. The cell cycle distribution was determined by flow 
cytometer, and data were analyzed by ModFit LT software; for each sample at least 
20,000 events were collected.[31] [34] [35] 
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CHAPTER 4 
 
CONCLUSION 
 
Stilbenes, chalcones, and flavanones which are plant secondary metabolites have 
biological activities such as anti-viral, anti-inflammatory, anti-bacterial, anti-fungal, and 
anti-cancer activities.  
In this study, previously synthesized 11 simple-stilbenes, simple-chalcones, 
simple-flavanones and 31 stilbene-fused chalcones and stilbene-fused flavanones were 
tested for their cytotoxic and anti-aromatase activities. The tested compounds were 
divided into four groups, according to their biological activities; the first group 
including C1, C5, F2, SC2, SC3, SC4, SC6, SC7, SC10, and SC11 showed both 
cytotoxic and aromatase inhibition activities. While the second group including C2, C3, 
SC1, SC5, SC8, SC9, SC12, F2, F3, SF10, SF11 showed only cytotoxic activity the 
third group including S1, S3, SF5, SF8, SF13, SF14, SF15, SF16 showed only 
aromatase inhibition activity. The last group including S2, S4, SC13, SC17, SF1, SF2, 
SF3, SF4, SF6, SF7, SF9, SF12, SF17 showed no activity.  
In addition, when the relationship between the structure and cytotoxic activity 
was evaluated it was seen that the simple-stilbenes have not cytotoxic activity while the 
simple-chalcones and stilbene-fused chalcones are cytotoxic. Therefore, it is clear that 
the stilbene-fused chalcones mimic the simple-chalcones. However, while the simple-
flavanones have cytotoxic activity, the stilbene-fused flavanones are not cytotoxic. This 
means that when the simple-flavanones are fused with stilbenes they loss their cytotoxic 
activity. In other words, the stilbene-fused flavanones mimic stilbenes. 
In this study, while one of the goals was investigation of the mimicking 
performance of the hybrid compounds, the other one was the exploration of compounds 
which have both cytotoxic and aromatase inhibition activity. However, while the twelve 
of the tested compounds had both cytotoxic and aromatase inhibition activity, the 
relationship between cytotoxic activity and aromatase inhibition could not be explained. 
More investigations should be done to understand the relationship between cytotoxic 
activity and aromatase inhibition as a future work. 
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